Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Minimal residual disease persists in bone marrow after adjuvant therapy
April 14th, 2005
Bone marrow aspirates taken up to 4 years after surgery for primary breast cancer from women receiving adjuvant therapy contained disseminated cancer cells, according to a study from England. M.J. Slade and colleagues at the Imperial College London said, "We have previously developed a quantitative polymerase chain reaction (QPCR) technique for the detection of cytokeratin 19 (CK19) transcripts in blood and bone marrow and compared this to immunocytochemistry (ICC). Together, both have shown promise for monitoring therapeutic efficacy in patients with metastatic breast cancer. "The aim of this study was to determine the feasibility and value of these...
Source: Women's Health Weekly (2005-04-14)
|
